Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 85,759 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Completed Phase 2 Interventional

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

NCT03770416
View directory record Official record
Conditions
Central Nervous System B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Interventions
Ibrutinib, Nivolumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Adaptations to Aerobic Exercise

NCT03360916
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo, Exercise Program
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Not applicable Interventional

Impact of Remote Foot Temperature Monitoring

NCT04345016
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Once-daily remote foot temperature monitoring
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Kensington, Maryland • Upper Marlboro, Maryland • Springfield, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 27, 2026, 11:50 AM EDT
Recruiting Not applicable Interventional

LINK-IT: Leveraging vIdeos and commuNity Health worKers to Improve Diabetes OuTcomes

NCT06319716
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Video-Based Diabetes Self-Management Education and Support (DSMES), Community Health Worker (CHW) Support
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 27, 2026, 11:50 AM EDT
Not yet recruiting Not applicable Interventional

Clinical Efficacy of Exoskeleton Assistance for Individuals Post-Stroke

NCT06064604
View directory record Official record
Conditions
Stroke
Interventions
Control, Hip Exoskeleton, Ankle Exoskeleton
Other · Device
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 27, 2026, 11:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

NCT04875806
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
Interventions
NC762
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
New Haven, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

NCT00293384
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 27, 2026, 11:50 AM EDT
Completed No phase listed Observational

Development of Computer-aided Detection and Diagnosis From Imaging Techniques

NCT00057252
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
139,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 27, 2026, 11:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

NCT06569147
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Elranatamab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Consumer Perceptions of Milk Beverages

NCT04272749
View directory record Official record
Conditions
Consumer Behavior
Interventions
Assess opinons on the milk beverages
Behavioral
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial

NCT02646449
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Mirtazapine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 27, 2026, 11:50 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ketamine for OUD and Comorbid Depression (OUDCD)

NCT05051449
View directory record Official record
Conditions
Opioid Use Disorder, Depressive Disorder
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Not applicable Interventional

Evaluation of Geistlich Fibro-Gide® in Comparison to CTG for the Treatment Around Implants

NCT04703738
View directory record Official record
Conditions
Soft Tissue Defect
Interventions
Soft tissue flap + Connective Tissue Graft, Soft tissue flap + Geistlich Fibro-Gide®
Procedure · Device
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Fullerton, California • Aurora, Colorado • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 11:50 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

NCT06257758
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
Interventions
VIO-01
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Lake Mary, Florida • Oklahoma City, Oklahoma • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 27, 2026, 11:50 AM EDT
Active, not recruiting Phase 1 Interventional

CART22 Alone or in Combination With huCART19 for ALL

NCT03620058
View directory record Official record
Conditions
Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
CART22-65s cells, huCART19 Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Phase 1 Interventional

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

NCT06945458
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KT-621
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
12
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 27, 2026, 11:50 AM EDT
Completed No phase listed Observational

Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures

NCT01445158
View directory record Official record
Conditions
Normal Donors
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years to 26 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

NCT02349048
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 27, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Results available

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

NCT02259348
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions
Cyclophosphamide, Fludarabine, G-CSF, Interleukin-2, Melphalan, Thiotepa, Rituximab, Natural killer cell therapy, T-cell depleted HPC transplant, CD45RA-depleted HPC transplant
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 27, 2026, 11:50 AM EDT
Active, not recruiting Phase 2 Interventional

Induction Chemotherapy for Locally Advanced Esophageal Cancer

NCT03110926
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
mFOLFOX6, Chemoradiation
Drug · Combination Product
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 27, 2026, 11:50 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 27, 2026, 11:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest

NCT00676585
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Normal Saline, Hydrocortisone
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 27, 2026, 11:50 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285
View directory record Official record
Conditions
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Interventions
KIN-2787, KIN-2787 and binimetinib
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 11:50 AM EDT
Terminated Not applicable Interventional Results available

CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)

NCT00748085
View directory record Official record
Conditions
Lung Cancer, Mesothelioma
Interventions
CryoSpray Ablation
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 27, 2026, 11:50 AM EDT